Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 2;14:1242194. doi: 10.3389/fphar.2023.1242194

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Li, Li, Guo, Tan, Xiang and Ouyang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In vivo OVX model and q-PCR experiments to validate the potential anti-OP effect of sitogluside. (A) μCT scanning of mice tibia showing the bone loss alleviated by sitogluside’s efficiency. (B) Statistical results of osteoporosis phenotype parameters of OVX mice, including BMD, Tb. Th, BV/TV, and Tb. N. (C) q-PCR results of osteogenic biomarker, which is shown to promote the osteogenic effect of sitogluside. (D) q-PCR results of OSX, which, treated with sitogluside or combined with the specific inhibitor of JNK (SP600125) and p38 (SB203580), indicates that sitogluside could target the JNK pathway to promote osteogenic genes in the treatment of OP.